In its latest 10-Q filing for Q1 2026, Assertio Holdings announced the sale of several older franchises including INDOCIN, SPRIX, Sympazan, CAMBIA, and OTREXUP to Cosette Pharmaceuticals, signaling a decisive portfolio shift. The company’s commercial focus now centers on ROLVEDON, a long-acting treatment for chemotherapy-induced neutropenia, which remains the primary revenue engine supported by proprietary technologies. Concurrently, Assertio has agreed to be acquired by Garda Therapeutics at $21.80 per share in cash, reflecting strategic repositioning for both entities. The operating model features external manufacturing and a single reportable segment largely dependent on sales execution, reimbursement environment, and supply continuity. Risks from supply chain dependencies, generics competition, and litigation remain material. Financially, the company holds manageable net debt with $33.7 million cash and $40 million convertible notes due in 2027.